Primary-source record
Upstream Bio announced plans to initiate Phase 3 trials of verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027. The company has completed key clinical, regulatory, and manufacturing milestones to support this. Ongoing Phase 2 trials in COPD and severe asthma long-term extension continue with data expected in H2 2027.
EX-99.1 2 upb-ex99_1.htm EX-99.1 EX-99.1 Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class efficacy and convenient quarterly dosing – WALTHAM, Mass. – November 10, 2026 - Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today reported financial results and business updates for the third quarter ended September 30, 2026. The Company highlighted its continued progress in developing verekitug to deliver potential best-in-class efficacy with quarterly dosing across three target indications: severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). Verekitug is the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin ( TSLP) receptor . “Our team is focused on the timely execution of startup activities for verekitug’s Phase 3 trials in severe asthma and CRSwNP. Preparations for the planned initiation of these trials in the first quarter of 2027 are well underway, with key clinical, regulatory, and manufacturing milestones now having been achieved,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio. “With the substantial and consistent clinical